Feasibility of co-transplantation of umbilical cord blood and third-party mesenchymal stromal cells after (non)myeloablative conditioning in patients with hematological malignancies. - 2024
Feasibility of co-transplantation of umbilical cord blood and third-party mesenchymal stromal cells after (non)myeloablative conditioning in patients with hematological malignancies.
Planken, Simon; De Becker, Ann; Kerre, Tessaet al.
2024 • In Current Research in Translational Medicine, 72, p. 103466
[en] Umbilical cord blood (UCB) is an alternative source of stem cells for patients lacking a 9/10 or 10/10 HLA identical donor. However, after UCB transplantation, time to engraftment and immune recovery are prolonged, increasing the risk of fatal complications. Mesenchymal stromal cells (MSC) can support hematopoietic engraftment and have immunosuppressive effects. The primary objective of this phase I/II multicenter study was to determine the feasibility and safety of UCB transplantation with co-infusion of third party MSC, as assessed by treatment related mortality (TRM) at day 100. Secondary objectives were engraftment, immune recovery, occurrence of graft versus host disease (GVHD), infections, disease free survival, relapse incidence and overall survival. Eleven patients were grafted according to this protocol. Allogeneic transplantation after co-infusion appears feasible with 18 % TRM at day 100. Engraftment data show a median time of 16 days to neutrophil and 27 days to platelet recovery, which is shorter than what is usually reported after UCB transplantation. Only 1 episode of acute GVHD was reported. In conclusion, MSC and UCB co-transplantation is feasible and might help overcome some of the drawbacks of UCB transplantation.
Disciplines :
Hematology
Author, co-author :
Planken, Simon ; Department of Hematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090 Brussels, Belgium and Research Group Hematology and Immunology, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium. Electronic address: simon.planken@uzbrussel.be
De Becker, Ann; Department of Hematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090 Brussels, Belgium and Research Group Hematology and Immunology, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium. Electronic address: ann.debecker@uzbrussel.be
Kerre, Tessa; UZ Gent, Department of Hematology - SCT Unit, Ghent, Belgium
Schoemans, Hélène; Department of Hematology, University Hospitals Leuven, Leuven, Belgium and Department of Public Health and Primary Care, ACCENT VV, KU Leuven - University of Leuven, Leuven, Belgium
Baron, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques
Graux, Carlos; CHU UCL Namur - Godinne, Department of Hematology, Yvoir, Belgium
Van Riet, Ivan; Department of Hematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090 Brussels, Belgium and Research Group Hematology and Immunology, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium
LECHANTEUR, Chantal ; Centre Hospitalier Universitaire de Liège - CHU > > Laboratoire de thérapie cellulaire et génique (LTCG)
BAUDOUX, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > > Laboratoire de thérapie cellulaire et génique (LTCG)
Schots, Rik; Department of Hematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090 Brussels, Belgium and Research Group Hematology and Immunology, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium
Beguin, Yves ; Université de Liège - ULiège > Département des sciences cliniques
Transplant Committee of the Belgian Hematology Society.
Language :
English
Title :
Feasibility of co-transplantation of umbilical cord blood and third-party mesenchymal stromal cells after (non)myeloablative conditioning in patients with hematological malignancies.
Snowden, J.A., et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 57:8 (2022), 1217–1239.
Tiercy, J.M., How to select the best available related or unrelated donor of hematopoietic stem cells?. Haematologica 101:6 (2016), 680–687.
Rocha, V., et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. New Engl J Med 342:25 (2000), 1846–1854.
Gluckman, E., et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord transplant group and the European blood and marrow transplantation group. N Engl J Med 337:6 (1997), 373–381.
Laughlin, M.J., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. New Engl J Med 344:24 (2001), 1815–1822.
Ballen, K., Umbilical cord blood transplantation: challenges and future directions. Stem Cells Transl Med 6:5 (2017), 1312–1315.
Barker, J.N., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105:3 (2005), 1343–1347.
Pittenger, M.F., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284:5411 (1999), 143–147.
Koç, O.N., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol, 18(2), 2000 p. 307-307.
Majumdar, M.K., et al. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 9:6 (2000), 841–848.
De Becker, A., Van Riet, I., Mesenchymal stromal cell therapy in hematology: from laboratory to clinic and back again. Stem Cells Dev 24:15 (2015), 1713–1729.
Le Blanc, K., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:9624 (2008), 1579–1586.
Remberger, M., Ringdén, O., Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients. Int J Hematol 96:6 (2012), 822–824.
Glucksberg, H., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:4 (1974), 295–304.
Lechanteur, C., et al. Clinical-scale expansion of mesenchymal stromal cells: a large banking experience. J Transl Med, 14(1), 2016, 145.
Baron, F., et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 16 (2010), 838–847.
Servais, S., et al. Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. Oncotarget 9:29 (2018), 20590–20604.
Servais, S., et al. Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: a multicenter prospective analysis. Front Immunol, 14, 2023, 1106464.
Ballen, K.K., et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 13:1 (2007), 82–89.
Rocha, V., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351:22 (2004), 2276–2285.
Brunstein, C.G., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 116:22 (2010), 4693–4699.
Parody, R., et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 12:7 (2006), 734–748.
Rocha, V., et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation 95:10 (2013), 1284–1291.
Anand, S., et al. Transplantation of Ex vivo expanded umbilical cord blood (NiCord) decreases early infection and hospitalization. Biol Blood Marrow Transplant 23:7 (2017), 1151–1157.
van Besien, K., et al. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica 101:5 (2016), 634–643.
Burke, M.J., et al. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant 17:6 (2011), 831–840.
Stagg, J., Galipeau, J., Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med, 13, 2013.
Passweg, J.R., et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European society for blood and marrow transplant activity survey report. Bone Marrow Transplant 52:6 (2017), 811–817.
Holtan, S.G., et al. Optimizing donor choice and GVHD prophylaxis in allogeneic hematopoietic cell transplantation. J Clin Oncol 39:5 (2021), 373–385.
